linjc16/ctgov huggingface dataset:
Review of Medical Records of Patients Who Have Been Treated With Lutetium at the Cross Cancer Institute Between January 2010 and April 30, 2014

Study Overview
=================
Brief Summary
-----------------
Retrospective review of the medical files of 115 patients with neuroendocrine tumours who were treated with Lutetium-177 DOTA-TATE under Health Canada's Special Access Programme (SAP) at the Cross Cancer Institute between January 2010 and April 30, 2014. Efficacy, safety, and other relevant data will be collected to support a separate clinical trial application.

Official Title
-----------------
Review of Medical Records of Patients Who Have Been Treated With Lutetium at the Cross Cancer Institute Between January 2010 and April 30, 2014

Conditions
-----------------
Neuroendocrine Tumors, NET

Intervention / Treatment
-----------------
* Drug: Lu-177 DOTA-TATE


Participation Criteria
=================
Eligibility Criteria
-----------------
Subjects with neuroendocrine tumours who received Lu-177 DOTA-TATE treatment under SAP at the Cross Cancer Institute between January 2010 and April 30, 2014.

Ages Eligible for Study
-----------------
Minimum Age: 14 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Lu-177 DOTA-TATE|The regimen used for therapy for patients treated under SAP was a standard dose of 5.55 GBq Lu-177 DOTA-TATE every 10-12 weeks for 4 treatments, then every 6 months as maintenance treatment.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Efficacy data on subjects with neuroendocrine tumours (NET) treated with Lu-177 DOTA-TATE | Data (Radioisotope and CT/MRI images, blood assays and Quality of Life Questionnaires, pre and post treatment) will be collected to determine tumor response of subjects with NET after treatment with Lu-177 DOTA-TATE. | Retrospective data January 2010 - April 30, 2014 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety and other relevant information on subjects treated with Lu-177 DOTA-TATE | Safety data will include blood counts and chemistry, GFR and adverse events, pre and post treatment. Other data includes patient demographics. | Retrospective data January 2010 - April 30, 2014 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Lu-177, Lutetium-177, DOTA-TATE, Neuroendocrine tumors, radiopharmaceutical
Getting Biased Treatment Study: How Psychotherapy and Antidepressants Change Brain Activity in Chronic Depression

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine how psychotherapy and pharmacotherapy respectively change brain activity in patients suffering from chronic depression.

Official Title
-----------------
Impact of Therapeutical Strategies on Emotional Processing in Depression: Neurofunctional and Clinical Issues in the Context of Affective Bias

Conditions
-----------------
Chronic Depression

Intervention / Treatment
-----------------
* Drug: Duloxetine
* Behavioral: Cognitive Behavioural Analysis System of Psychotherapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Chronic Depression (Double Depression, Chronic MDE, MDE with incomplete remission) HAMD-24>20 Exclusion Criteria: Concurrent Psychotherapy or Psychopharmacotherapy Previous Non-Response to Duloxetine Non-Response to three Antidepressants of two different groups given at adequate doses or Non-Response to two empirically tested forms of Psychotherapy in the current Depressive Episode Serious Psychiatric comorbidity Serious Neurologic comorbidity Contraindications to Duloxetine Contraindications to fMRI

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: AD<br>Antidepressant Duloxetine | Drug: Duloxetine<br>* Duloxetine 30mg up to 120mg per day.<br>|
| Active Comparator: PT<br>Psychotherapy (CBASP) - Cognitive Behavioural Analysis System of Psychotherapy | Behavioral: Cognitive Behavioural Analysis System of Psychotherapy<br>* Cognitive Behavioural Analysis System of Psychotherapy (CBASP): 20 sessions of psychotherapy, beginning with twice weekly, then weekly sessions.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Neuroimaging Data (fMRI) |  | Before and After Therapy | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| HAMD |  | Weekly | 
| Salivary Cortisol |  | Before and After Therapy | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Depression, Duloxetine, Psychotherapy, Magnetic Resonance Imaging
A Rollover Study to Provide Chronic T-1249 to Patients Who Completed Study T1249-102

Study Overview
=================
Brief Summary
-----------------
Patients who complete study T1249-102 (must be currently failing a T-20 containing regimen to participate in this study) will receive T-1249 at a dose of 200mg daily in combination with a background antiretroviral regimen for 96 weeks. Only patients that participated in study T1249-102 can participate in study T1249-105.

Conditions
-----------------
HIV Infections

Intervention / Treatment
-----------------
* Drug: T-1249


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Completion T1249-102; Currently failing a T-20 containing regimen Exclusion Criteria: Non-completion of T1249-102.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: T-1249|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Treatment Experienced
Functional Magnetic Resonance Imaging - Synthetic Aperture Magnetometry (fMRI-SAM) and Alzheimer's Disease

Study Overview
=================
Brief Summary
-----------------
The aim of the protocol is to study the resting brain activation profile of 3 groups of people, using a new fMRI procedure, called fMRI-SAM. fMRI-SAM will be applied to 25 Alzheimer's disease (AD) patients, 25 patients suffering from amnestic - mild cognitive impairment (MCI) - a clinical picture which may be a prodromal form of AD - and 60 healthy controls. The first analysis of the data will search differences of brain activation profiles between the 3 groups. In the second step, the investigators will study the predictive value of fMRI-SAM to detect MCI patients who will later convert to AD.

Official Title
-----------------
Evaluation of fMRI-SAM in the Early Detection of Alzheimer's Disease.

Conditions
-----------------
Alzheimer's Disease

Intervention / Treatment
-----------------
* Procedure: fMRI to detect MCI patients who will convert to Alzheimer's disease


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Alzheimer's disease of mild to moderate severity (25 patients) Amnestic MCI patients (25 patients) 55-75 year-old patients Exclusion criteria: Any other cause of dementia for AD patients Any stroke Any disease with a negative vital prognosis

Ages Eligible for Study
-----------------
Minimum Age: 55 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: ALZHEIMER DISEASE<br> | Procedure: fMRI to detect MCI patients who will convert to Alzheimer's disease<br>* There is a fMRI to be realized in the 3 arms. No drug is administered<br>|
| Other: MOLD COGNITIVE IMPAIRMENT<br> | Procedure: fMRI to detect MCI patients who will convert to Alzheimer's disease<br>* There is a fMRI to be realized in the 3 arms. No drug is administered<br>|
| Other: CONTROLS<br> | Procedure: fMRI to detect MCI patients who will convert to Alzheimer's disease<br>* There is a fMRI to be realized in the 3 arms. No drug is administered<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Comparing fMRI data between 3 groups of subjects: MCI, Alzheimer's disease and normal subjects |  | 1, 5 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Follow-up of MCI patients at 6, 12 and 18 months to detect a conversion to Alzheimer's disease |  | Prediction of Alzheimer's disease on fMRI data |
InFLUenza and the HEART An Investigation Into the Acute and Lasting Cardiac Effects of Influenza Infection

Study Overview
=================
Brief Summary
-----------------
Influenza and the Heart: An investigation into the acute and lasting cardiac effects of influenza infection the investigators aim to assess the mechanisms for cardiovascular disease in patients suffering an acute influenza infection. The project will be carried out by creating a prospective clinical cohort study of consecutive patients hospitalized at Herlev & Gentofte University Hospital with a laboratory confirmed influenza.

Official Title
-----------------
Influenza and the Heart: An Investigation Into the Acute and Lasting Cardiac Effects of Influenza Infection

Conditions
-----------------
Influenza, Cardiovascular Complication

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients hospitalized at Herlev & Gentofte University Hospital with a laboratory-confirmed diagnosis of influenza > 18 years of age Exclusion Criteria: Persons not able to cooperate Persons unable to understand and sign informed consent Pregnancy Persons simultaneously positive with COVID-19

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients developing cardiovascular complications | Including new-onset heart failure, worsening of current heart failure, acute myocardial infarction, and cardiac arrest | 3 years | 
| Number of patients developing in-hospital mortality |  | 3 years | 
| Rate of cardiac dysfunction | Defined by impaired echocardiographic parameters and elevated cardiac biomarkers - NT - pro - BNP annd hs - TNT | 3 years | 
| Prevalence of elevated biomarkers of infection/inflammation | Prevalence of elevated biomarkers of infection/inflammation and it association with cardiac dysfunction | 3 years | 
| Rate of pulmonary embolisms diagnosed with CT thorax angiography |  | 3 years |
Comparison Between the Histological and Clinical Diagnosis of Non Healing Wounds

Study Overview
=================
Brief Summary
-----------------
50 patients with non healing wounds will undergo biopsy to conclude wether there is an occult etiology for the wound.

Detailed Description
-----------------
25 patients suffering from non healing wounds which have non typical features for the clinical diagnosis (such as pale granulation, raised lesions and more) will undergo biopsy of the wound. Another 25 patients suffering from non healing wounds with typical features for the clinical diagnosis will undergo biopsy of the wound. The hypothesis is that non healing wounds harbor undiagnosed etiologic factors such as BCC, SCC, vasculitis etc. and that some clinical features should raise our suspicion for these occult etiologies.

Official Title
-----------------
Comparison Between the Histological and Clinical Diagnosis of Non Healing Wounds

Conditions
-----------------
Wounds and Injuries

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with non-healing wounds (for > 6 weeks) consent to be included in the study age 18-85 Exclusion Criteria: patients taking anti coagulant therapy patients taking steroids or immunosuppressive therapy pregnancy pace maker

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| HISTOLOGY RESULTS | HISTOLOGY RESULTS OF ALL WOUND BIOPSIES WILL BE COLLECTED TO ASSESS THE ACCULT ETIOLOGY RATE IN NON HEALING WOUNDS. | 04/2013 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
BCC, Problem wounds, Non healing wounds, SCC, Vasculitis
Reassessment Strategy in the Diagnosis of Coronary Heart Disease in Elderly

Study Overview
=================
Brief Summary
-----------------
Despite the effectiveness of beta-blockers and antiplatelet agents for secondary prevention of coronary heart disease, this treatments are underused in the elderly because of diagnosis uncertainty and underuse of efficient treatment. in a first time, diagnosis reassessment with invasive technique if necessary. in a second time, treatment reassessment.

Detailed Description
-----------------
not desired

Official Title
-----------------
Therapeutical Impact of a Reassessment Strategy in the Diagnosis of Coronary Heart Disease in Elderly

Conditions
-----------------
Myocardial Ischemia

Intervention / Treatment
-----------------
* Other: diagnosis reassessment
* Other: Diagnosis strategy and subsequent therapeutic reassessment


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients 75 of age or older hospitalized in a geriatric service and suspect of coronary heart disease Exclusion Criteria: acute myocardial infarction

Ages Eligible for Study
-----------------
Minimum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>Diagnosis strategy and subsequent therapeutic reassessment All patients are in that arms. They all receive the diagnosis reassessment strategy. | Other: diagnosis reassessment<br>* Strategy of diagnosis reassessment following a decision tree.<br>* Other names: no other names to specified;Other: Diagnosis strategy and subsequent therapeutic reassessment<br>* Performed by geriatricians, following a decision tree, based on medical history, electrocardiogram, cardiac echotomography and stress scintigraphy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| therapeutical impact of a reassessment strategy in the diagnosis of coronary heart disease in elderly |  | during hospitalization | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| part link, in the treatment modification, with diagnosis reassessment and the part link with treatment optimization, death and rehospitalization in the subsequent 6 and 12 months |  | during hospitalization | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Veterans
Lyme Borreliosis and Early Cutaneous Diagnostic

Study Overview
=================
Brief Summary
-----------------
Test and evaluate a new diagnostic method (SRM-MS/MS: Selected Reaction Monitoring- Mass spectrometry) for Lyme Borreliosis on human skin biopsies. Patients included are those with the early skin manifestation (erythema migrans). This new proteomic method will be compared to the two existing method: culture of Borrelia and PCR detection of Borrelia (DNA detection of the bacteria).

Official Title
-----------------
Lyme Borreliosis and Early Cutaneous Diagnostic

Conditions
-----------------
Erythema Migrans

Intervention / Treatment
-----------------
* Procedure: Skin biopsies


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Erythema migrant as criteria EUCALB or atypical form associated to tick's sting Patient having signed a consent Patient affiliated to a social security scheme Exclusion Criteria: Prior treatment with antibiotics Erythema migrans on the face Bleeding disorders Anticoagulant treatment Inability to give clear information (subject in an emergency situation, understanding of the topic difficulty, ...)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: SRM / MS-MS<br> | Procedure: Skin biopsies<br>* Skin biopsies of patients with Lyme disease (erythema migrans) infected with Borrelia burgdorferi sensu lato will be analyzed by three diagnostic techniques : molecular technique (PCR), biological technique (culture of the bacteria) and proteomics technique (SRM/ MS-MS)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Compare the sensitivity (percentage of positive tests) of the SRM / MS-MS to techniques of PCR and culture Borrelia | percentage of positive tests with all three techniques (SRM/MS-MS ; PCR ; culture) | One year study | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
erythema migrans, Lyme, early diagnosis, skin biomarkers, proteomics diagnostic, mass spectrometry
Medial Patellofemoral Ligament Reconstruction With or Without Lateral Retinaculum Release

Study Overview
=================
Brief Summary
-----------------
The investigators hypothesis is lateral retinaculum release has no effect on treatment of Patellar Recurrent Dislocation with Medial Patellofemoral Ligament (MPFL) reconstruction.

Official Title
-----------------
Randomized Control Trial on Lateral Retinaculum Release in MPFL Reconstruction

Conditions
-----------------
Episodic Patellar Dislocation

Intervention / Treatment
-----------------
* Procedure: MPFL reconstruction and lateral retinaculum release
* Procedure: conventional surgery


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age between 18yo and 45yo indication for MPFL reconstruction unilateral or bilateral indication Exclusion Criteria: indication for bony procedures previous surgery for PF disorders patient refusal

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: isolated MPFL reconstruction<br> | Procedure: conventional surgery<br>* conventional surgery: MPFL reconstruction<br>|
| Experimental: MPFL reconstruction and Lateral retinaculum release<br> | Procedure: MPFL reconstruction and lateral retinaculum release<br>* MPFL is performed with a standard technique using gracilis tendon. A tunnel is performed at the femoral part with a bioabsorbable screw fixation and 2 bundles with suture fixation at the patellar side<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patellar tilt measurement | IKDC score, patellar tilt measurement on x-rays and CT-scan | 2 years of follow up | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| rate of complications |  | 2 years of follow up | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
dislocation, MPFL, patella, release
Simultaneous Measurement of Electroencephalography (EEG) and Functional Magnetic Resonance Imaging (fMRI) in Patients With Alcoholism

Study Overview
=================
Brief Summary
-----------------
Investigation of inpatients with alcoholism after detoxification with simultaneous Electroencephalography (EEG) and functional Magnetic Resonance Imaging (fMRI).

Official Title
-----------------
Neurobiological Correlates of Disturbed Cognitive Function in Patients With Alcoholism - Simultaneous Measurement With EEG and fMRI

Conditions
-----------------
Alcoholism

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age of 18 or more Inpatient with alcoholism after detoxification. Exclusion Criteria: Neurological disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Patients with alcoholism according to ICD-10 after detoxification